Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea
· Delayed Price · Currency is KRW 1,641,000
-39,000 (-2.32%)
At close: Dec 5, 2025
Samsung Biologics Revenue
Samsung Biologics had revenue of 1.66T KRW in the quarter ending September 30, 2025, with 39.86% growth. This brings the company's revenue in the last twelve months to 5.50T, up 26.13% year-over-year. In the year 2024, Samsung Biologics had annual revenue of 4.55T with 23.08% growth.
Revenue (ttm)
5,504.84B
Revenue Growth
+26.13%
P/S Ratio
13.80
Revenue / Employee
1.15B
Employees
4,770
Market Cap
75.96T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4,547.32B | 852.73B | 23.08% |
| Dec 31, 2023 | 3,694.59B | 693.29B | 23.10% |
| Dec 31, 2022 | 3,001.30B | 1,433.29B | 91.41% |
| Dec 31, 2021 | 1,568.01B | 403.23B | 34.62% |
| Dec 31, 2020 | 1,164.78B | 463.19B | 66.02% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |
| HLB Co., Ltd. | 80.73B |
Samsung Biologics News
- 5 weeks ago - Samsung BioLogics Co Ltd (XKRX:207940) Q3 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
- 2 months ago - Korean Stock Market Declines Amid Trade Uncertainty; Samsung Biologics (SSNLF) Drops - GuruFocus
- 2 months ago - Asian drug market stocks slides: Trump’s 100% pharmaceutical tariffs shake market; broader impact on Japan likely minimal - The Times of India